CLRB — Cellectar Biosciences, Inc.

Summary of Cellectar Biosciences, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended 2025 with $13.2 million in cash and cash equivalents, down from $23.3 million in 2024. Raised $5.8 million in Q4 2025.
• Expenses:
  • Research and Development (R&D) expenses decreased to $11.5 million in Q4 2025 from $26.6 million in Q4 2024, primarily due to the conclusion of patient enrollment in the CLOVER-WaM study.
  • General and Administrative (SG&A) expenses also decreased to $11.5 million from $25.6 million, attributed to reduced pre-commercialization efforts.
• Net Loss: Reported a net loss of $21.8 million for 2025, or $8.35 per share, significantly improved from a loss of $44.6 million in 2024.

2. Strategic Updates and Business Highlights

• Iapocine I-131:
  • Progressing towards a conditional marketing authorization application in Europe expected in 2026, with potential commercialization as early as 2027.
  • Received FDA Breakthrough Therapy designation and is on track for an NDA submission under the accelerated approval pathway.
• Pipeline Development:
  • Initiated a Phase 1b study of CLR125 for triple-negative breast cancer (TNBC).
  • Strengthened supply partnerships for CLR225, enhancing clinical development capabilities.
• Intellectual Property: Expanded patent portfolio across multiple regions, enhancing protection for key assets.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipate a milestone-rich year with multiple data presentations, including twelve-month follow-up data from the CLOVER-WaM study, expected to bolster the regulatory submission strategy.
• Market Potential: The addressable market for Iapocine in the U.S. and Europe is significant, with estimates of approximately 12,000 patients in the U.S. and over 13,000 in Europe for the second-line setting.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: The decline in cash reserves raises concerns about funding operations beyond 2026 without additional capital raises.
• Regulatory Risks: While there is optimism surrounding regulatory submissions, the success of these applications is contingent on meeting FDA and EMA requirements, which can be unpredictable.
• Market Competition: The company faces competition from established therapies in the oncology space, particularly in the BTK inhibitor market, which may impact market penetration.

5. Notable Q&A Insights

• Regulatory Submission Strategy: Management confirmed that the data package for the EMA submission will largely overlap with that for the FDA, facilitating a more streamlined process.
• Enrollment Expectations: High interest from physicians and patients in participating in upcoming trials, particularly for Iapocine, is anticipated to drive enrollment speed.
• Data Expectations: The twelve-month follow-up data is expected to show improvements in response rates and durability compared to previous data, enhancing the case for accelerated approval.
• Market Dynamics: The transition of BTK inhibitors to first-line therapy is changing the treatment landscape, with the potential for Iapocine to fill a significant unmet need in the second-line setting.

Overall, Cellectar Biosciences demonstrated significant progress in 2025, with a focus on advancing its clinical pipeline and regulatory strategy, while also facing challenges related to cash management and competitive pressures in the oncology market.